EPHA2 and neoplasm: In this approach, a secretory bispecific T-cell engager, consisting of antibodies directed against CD3 and a tumor cell-specific antigen, EphA2, was expressed by an oncolytic vaccinia virus, and resulted in improved anti-tumor efficacy via activation of T-cells within tumors and bystander cell killing (109).